- Conditions
- Hepatitis C Virus
- Interventions
- Ortho Tri-Cyclen®, BMS-650032
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 58
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
- Interventions
- Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2)
- Drug
- Lead sponsor
- Food and Drug Administration (FDA)
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- QTc Interval, Pharmacokinetics
- Interventions
- Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
- Drug
- Lead sponsor
- Usona Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Hepatitis C
- Interventions
- BMS-791325, Moxifloxacin, Placebo matching BMS-791325
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Healthy Subjects
- Interventions
- Placebo, E2609, Moxifloxacin
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy
- Interventions
- sisunatovir, placebo, moxifloxacin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Health Adult Subjects
- Interventions
- Omaveloxolone, Moxifloxacin
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Epilepsy
- Interventions
- BIA 2-093, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Bial - Portela C S.A.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Miramar, Florida
- Conditions
- Healthy Volunteers
- Interventions
- CTP-543, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cardiac Repolarization, Healthy Volunteers
- Interventions
- Balinatunfib, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Intracameral Antibiotics, Cataract Surgery, Phacoemulsification, Endophthalmitis, Vancomycin, Moxifloxacin
- Interventions
- Vancomycin, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Panhandle Eye Group, LLP
- Other
- Eligibility
- 30 Years to 100 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Amarillo, Texas
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics, intravenous antibiotics
- Drug · Procedure
- Lead sponsor
- Julio Ramirez
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Healthy
- Interventions
- sotagliflozin, oral contraceptive, oral contraceptive + sotagliflozin
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2015
- U.S. locations
- 2
- States / cities
- Evansville, Indiana • Dallas, Texas
- Conditions
- Healthy Volunteers
- Interventions
- Epetraborole and matching placebo, Epetraborole, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- AN2 Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Drug Toxicity
- Interventions
- HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Functional Dyspepsia
- Interventions
- YM443, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Healthy
- Interventions
- ALS-008176, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy Subjects
- Interventions
- MT-7117, moxifloxacin, Placebo
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas
- Conditions
- Healthy
- Interventions
- LX4211 800 mg, LX4211 2000 mg, moxifloxacin 400 mg, LX4211 Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Healthy
- Interventions
- JNJ-54861911-Therapeutic Dose, JNJ-54861911 - Supratherapeutic Dose, JNJ-54861911-Matched Placebo, Moxifloxacin, Moxifloxacin Matched Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy Volunteer
- Interventions
- Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Healthy Volunteers
- Interventions
- BMS-986278, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Pharmacokinetics
- Interventions
- monophasic oral contraceptive, AZD7325
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas